Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: A tissue doppler study

Echocardiography

Volumn 27, Issue 5, 2010, Pages 512-518

  Pala, Selcuk ^a   Esen, Özlem ^b   Akçakoyun, Mustafa ^a   Kahveci, Gökhan ^c   Kargin, Ramazan ^a   Tigen, Kürşat ^a   Karaahmet, Tansu ^a   Açar, Göksel ^a   Esen, Ali Metin ^a   Kirma, Cevat ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b MEMORIAL HOSPITAL   (Turkey)

^c Rize Devlet Hastanesi   (Turkey)

Author keywords

Myocardial systolic velocity; Pioglitazone; Rosiglitazone; Thiazolidinedione; Tissue Doppler imaging

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART AFTERLOAD; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE VARIABILITY; HUMAN; M MODE ECHOCARDIOGRAPHY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SYSTOLE; THIAZOLIDINEDIONES;

EID: 77952945502     PISSN: 07422822     EISSN: 15408175     Source Type: Journal    
DOI: 10.1111/j.1540-8175.2009.01083.x     Document Type: Article

References (23)

1. Asakawa M, Takano H, Nagai T, et al : Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002 105 : 1240 1246.
2. Yamamoto K, Ohki R, Lee RT, et al : Peroxisome proliferator activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001 104 : 1670 1675.
3. Bishop-Bailey D : Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000 129 : 823 834.
4. Takano H, Nagai T, Asakawa M, et al : Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000 87 : 596 602.
5. Stumvoll M, Haring H : Glitazones: Clinical effects and molecular mechanisms. Ann Med 2002 34 : 217 224.
6. Nesto RW, Bell D, Bonow RO, et al : American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003 108 : 2941 2948.
7. Masoudi FA, Wang Y, Inzucchi SE, et al : Metformin and thiazolidinedione use in Medicare patients with heart failure. J Am Med Assoc 2003 290 : 81 85.
8. Delea TE, Edelsberg JS, Hagiwara M, et al : Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study. Diabetes Care 2003 26 (11 2983 2989.
9. St John Sutton M, Rendell M, Dandona P, et al : A comparison of theeffects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002 25 : 2058 2064.
10. Dargie HJ, Hildebrandt PR, Riegger GA, et al : A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007 49 : 1696 1704.
11. Ghazzi MN, Perez JE, Antonucci TK, et al : Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997 46 : 433 439.
12. Sung BH, Izzo JL Jr., Dandona P, et al : Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999 34 (1 83 88.
13. Türkmen Kemal Y, Güvener Demirag N, Yildirir A, et al : Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus. Acta Diabetol 2007 44 (3 149 156.
14. Brunani A, Liuzzi A, Titon A, et al : Evaluation of rosiglitazone administration on cardiovascular function in severe obesity. Clin Cardiol 2008 31 (12 602 606.
15. Giles TD, Miller AB, Elkayam U, et al : Pioglitazone and heart failure: Results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008 14 (6 453 455.
16. Shimoyama M, Ogino K, Tanaka Y, et al : Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999 48 (3 609 615.
17. Furuse Y, Ogino K, Shimoyama M, et al : Ca(2+)-sensitizing effect is involved in the positive inotropic effect of troglitazone. Br J Pharmacol 2001 133 (8 1307 1313.
18. Ogino K, Furuse Y, Uchida K, et al : Troglitazone improves cardiac function in patients with congestive heart failure. Cardiovasc Drugs Ther 2002 16 (3 215 220.
19. Nemoto S, Razeghi P, Ishiyama M, et al : PPAR-gamma agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation. Am J Physiol Heart Circ Physiol 2005 288 (1 H77 H82.
20. Uchida K, Ogino K, Shimoyama M, et al : Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts. Eur J Pharmacol 2000 400 (1 113 119.
21. Tsuji T, Mizushige K, Noma T, et al : Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 2001 38 (6 868 874. (Pubitemid 33104697)
22. Horio T, Suzuki M, Suzuki K, et al : Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005 18 (7 949 957.
23. Terui G, Goto T, Katsuta M, et al : Assessment of left ventricular diastolic function with pioglitazone in type 2 diabetic patients. J Cardiol 2006 48 (5 263 267.